Nuwellis Secures $50M Funding: A Bold Step Forward in Restoring Fluid Balance & Renewing Hope

Nuwellis, Inc. is proud to announce that it has successfully raised $50,000,000 in new funding—a strong endorsement of its mission to restore fluid balance and renew hope for patients worldwide. As a publicly traded medical technology company listed on Nasdaq (NUWE) and headquartered in Eden Prairie, Minnesota, Nuwellis has been at the forefront of innovation since 2012. With a wholly owned subsidiary in Ireland, the company is committed to improving patient care by addressing fluid overload, a critical challenge faced by individuals suffering from heart failure, critical illnesses, and other complex conditions. The new investment will be strategically deployed to further advance the Aquadex SmartFlow® system—a groundbreaking solution that provides clinicians with a precise, safe, and flexible method for removing excess fluid. Designed for patients weighing 20 kg or more, Aquadex is already making a significant impact in hospital settings, where fluid management can be challenging and treatment outcomes are vital. The infused capital will support ongoing research and clinical trials, propel next-generation product development, and expand the operational capacity needed to meet growing global demand. This funding round reinforces Nuwellis’ vision of transforming patient care by equipping healthcare professionals with innovative tools designed for clinical impact. In addition, it underscores the confidence that investors have in the company’s commitment to enhancing patient outcomes and supporting the dedicated care teams responsible for driving meaningful change. For more information about Nuwellis and its transformative work in medical technology, please visit nuwellis.com.